Rutgers Study Quantifies Rare Vision Risk for GLP-1 Drugs Amidst Legal Backlash
A new study from Rutgers University links popular GLP-1 medications, including Ozempic and Wegovy, to a slightly elevated risk of ischemic optic neuropathy, a rare condition causing sudden and potentially permanent vision loss. While the absolute risk is low, estimated at three to four additional cases per 10,000 patients over 18 months, the findings highlight the need for vigilance among millions of users. This scientific data emerges as hundreds of lawsuits allege that manufacturers failed to warn patients about this specific side effect.